{
}
Amgen's obesity drug, MariTide, demonstrated up to 20% weight loss in a Phase 2 trial, aligning with existing treatments like Zepbound and Wegovy. However, a higher dropout rate due to side effects raised concerns, leading to a decline in Amgen's stock. The company plans to initiate a Phase 3 study to further evaluate MariTide's efficacy and safety.
Eli Lilly"s experimental cholesterol pill, muvalaplin, has shown promising results in a mid-stage trial, significantly reducing levels of lipoprotein(a), a genetic risk factor for heart disease. The highest dose decreased Lp(a) by 70% compared to placebo, with a favorable safety profile. Analysts suggest the drug could become a blockbuster if it proves effective in preventing cardiovascular events in future trials.
Regeneron Pharmaceuticals' shares dropped nearly 10% as third-quarter sales of Eylea fell short of expectations, raising concerns about future sales amid competition. In contrast, Madrigal Pharmaceuticals reported strong sales of its MASH drug, Rezdiffra, totaling $62 million, significantly exceeding forecasts. UCB's Alzheimer’s drug trial showed promising secondary results despite missing its main goal, while AbbVie announced a partnership with EvolveImmune Therapeutics to develop cancer therapies.
Eli Lilly's third-quarter earnings fell short of Wall Street expectations, with revenue at $11.4 billion, missing forecasts of $12.1 billion. Sales of its obesity drugs, Mounjaro and Zepbound, reached $3.1 billion and $1.26 billion, respectively, but were lower than anticipated, leading to a significant drop in shares and a revised revenue guidance for the year. Despite these setbacks, company executives noted continued growth in underlying demand for their products.
A multibillion-dollar race is underway among pharmaceutical companies to develop superior obesity drugs, with key contenders like Eli Lilly's Zepbound and Novo Nordisk's Wegovy leading the market. Upcoming trial results for various drugs, including Amgen's maritide and Roche's CT-996, are highly anticipated and could reshape the competitive landscape. As companies explore innovative approaches, such as preserving muscle mass during weight loss, the future of obesity treatment remains dynamic and closely watched.
David Risinger
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
amgen obesity drug mariTide shows promise but falls short of expectations
United States Dollar
Amgen Inc.
Novo Nordisk A/S
Eli Lilly and Company
USA
David Risinger
Michael Yee
Show more
01:00 26.11.2024
ura and dexcom partner to enhance metabolic health tracking for users
Novartis AG
DexCom, Inc.
Veritone, Inc.
Eli Lilly and Company
Oura
USA
Matt Dolan
Ruth Gimeno
Annika Constantino
David Risinger
Tom Hale
Show more
22:04 19.11.2024
regeneron faces sales uncertainty while madrigal reports strong drug launch results
United States Dollar
Regeneron Pharmaceuticals, Inc.
H. Lundbeck A/S
AbbVie Inc.
PTC Therapeutics, Inc.
UCB SA
USA
Alistair Henry
David Risinger
Joseph Schwartz
Brian Abrahams
Show more
11:06 01.11.2024
lilly shares drop as obesity drug sales fall short of expectations
United States Dollar
Eli Lilly and Company
Novo Nordisk A/S
USA
David Ricks
David Risinger
Lucas Montarce
Show more
14:45 30.10.2024
pharmaceutical race intensifies for next generation obesity treatments
United States Dollar
Eli Lilly and Company
Pfizer Inc.
Novo Nordisk A/S
Hoffmann-La Roche AG
Amgen Inc.
USA
DNK
Joe Biden
Donald Trump
David Risinger
Show more
11:49 10.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Government Economic Policies
Workplace Trends
Industry Mergers & Acquisitions
Stock Market Updates
Fintech Startups
Venture Capital Investments
Financial Scams and Security
Finance Mergers & Acquisitions
CEO Changes
Cryptocurrency Trends
Emerging Startups
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: